Article
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.
Nature communications - 10 Aug 2026
Zhou Fei, Su Chunxia, Liang Wenhua, Xu Li-Di, Tao Wei, Qian Juanjuan, Xu Shidong, Liu Dan, Fan Rui, Zhang Yaxi, Liu Yiqian, Wu Lin, Fu Xiangning, Zhang Xiaodong, Shen Ning, Ge Di, Chen Qun, Mao Weimin, Xu Lin, Chen Chun, Hu Bing, Shao Guoguang, Hu Jian, Zhao Jian, Liu Xiaoqing, Liu Zhidong, Wang Zheng, Xiao Zemin, Gong Taiqian, Lin Wen, Li Xingya, Ye Feng, Liu Yang, Ma Haitao, Huang Yunchao, Zhou Jianying, Wang Zhonglin, Fu Junke, Ding Lieming, Mao Li, Chen Weizhi, He Jianxing, Zhou Caicun
Abstract excerpt
Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EVIDENCE trial, which includes patients with stage II-IIIA resected EGFR-mutated NSCLC who have received either adjuvant icotinib or...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- Neoplasm, Residual